A Clinical Feasibility Evaluation of the MicroStent Peripheral Vascular Stent in Subjects With Artery Lesions Below the Knee
Status: | Not yet recruiting |
---|---|
Conditions: | Peripheral Vascular Disease |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 21 - Any |
Updated: | 4/17/2018 |
Start Date: | April 2018 |
End Date: | July 2021 |
Contact: | Sarrah Val |
Email: | sval@micromedicalsolutions.net |
Phone: | 312-208-8670 |
This prospective feasibility study is a single arm, non-randomized multi-center study
evaluating the safety and performance of the MicroStent peripheral vascular stent system for
use in arterial lesions below the knee. A total of 15 subjects will be enrolled at 3 centers
and followed for up to 3 years, with the primary safety and efficacy endpoints evaluated 30
days post-implant.
evaluating the safety and performance of the MicroStent peripheral vascular stent system for
use in arterial lesions below the knee. A total of 15 subjects will be enrolled at 3 centers
and followed for up to 3 years, with the primary safety and efficacy endpoints evaluated 30
days post-implant.
General Inclusion Criteria:
- Subject is male or non-pregnant female adult over the age of 21
- Subject has documented clinical evidence of critical limb ischemia (CLI) in the target
limb prior to the study procedure, with a Rutherford classification score of 4-5
- Subject, or subject's designated legal representative, has been informed of the nature
of the study and is willing to provide written informed consent
- Subject is geographically stable and is able and willing to comply with all study
required follow up visits.
- Subject has a life expectancy > 1 year
Angiographic Inclusion Criteria
- Target limb has at least a single vessel with runoff to the foot
- Subject has up to 3 non-contiguous lesions, each with >=70% stenosis and <=5.0cm in
length located at or distal to the tibial-peroneal trunk and above the ankle;
including the anterior tibial, posterior tibial, or peroneal arteries
- Target lesion(s) has a reference vessel diameter of 2.5 - 4.5mm to accommodate the
test article.
- Target lesion(s) is able to be crossed with a guidewire to facilitate treatment with
the study device.
General Exclusion Criteria:
- Subject has a prior or planned index limb amputation above the ankle.
- Subject has a wound/ulcer located on the target limb with a Wound, Ischemia, and foot
Infection (WIfI) infection grade >1
- Subject is pregnant, plans to become pregnant, or is nursing.
- Subject is morbidly obese or has other clinical conditions that severely inhibit X-ray
visualization
- Subject has a history of coagulation/clotting disorders, acute thrombosis, or is
hypercoagulable
- Subject has allergy to iodinated contrast media
- Subject is in acute renal failure
- Subject has active systemic infection
- Subject is participating in another research study involving an investigational
device, biologic, or drug that has not completed the primary endpoint at the time of
enrollment
- Subject has other comorbidities that, in the opinion of the investigator, preclude
them from receiving study treatment and/or from completing the required study follow
up assessments.
- Subject has had any non-diagnostic endovascular or surgical procedure in the lower
extremities less than 14 days prior or planned less than 30 days after the index
procedure
- Subject presents with acute limb ischemia or acute thrombosis of the target limb.
- Subject has experienced myocardial infarction, thrombolysis, or angina less than 30
days prior to the index procedure.
- Subject has a history of stroke within 3 months of the index procedure.
Angiographic exclusion criteria
- Presence of hemodynamically significant inflow lesions >15cm in length
- Failure to obtain <= 30% residual stenosis in hemodynamically significant inflow
lesions <=15cm in length
- Failure to obtain <=30% residual stenosis in hemodynamically significant non-target
infrapopliteal lesions
- In the opinion of the investigator, subject may require use of alternative therapy
(e.g. atherectomy, etc.)
We found this trial at
2
sites
Houma, Louisiana 70360
Principal Investigator: Craig Walker, MD
Click here to add this to my saved trials
Click here to add this to my saved trials